67 related articles for article (PubMed ID: 20197202)
1. Cloning and expression of canine CD25 for validation of an anti-human CD25 antibody to compare T regulatory lymphocytes in healthy dogs and dogs with osteosarcoma.
Rissetto KC; Rindt H; Selting KA; Villamil JA; Henry CJ; Reinero CR
Vet Immunol Immunopathol; 2010 May; 135(1-2):137-145. PubMed ID: 20197202
[TBL] [Abstract][Full Text] [Related]
2. TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4(+)CD25 (+) Treg apoptosis.
Diao Z; Shi J; Zhu J; Yuan H; Ru Q; Liu S; Liu Y; Zheng D
Cancer Immunol Immunother; 2013 Apr; 62(4):653-63. PubMed ID: 23143747
[TBL] [Abstract][Full Text] [Related]
3. Depletion of CD4(+)CD25(+) regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma.
Chen YL; Fang JH; Lai MD; Shan YS
World J Gastroenterol; 2008 Oct; 14(38):5797-809. PubMed ID: 18855977
[TBL] [Abstract][Full Text] [Related]
4. Preparation and application of fluorescent monoclonal antibodies recognizing goat CD4
Wang Y; Yang H; Hu J; Jiang Y; Ma W; Gao S; Chen D
Appl Microbiol Biotechnol; 2024 May; 108(1):327. PubMed ID: 38717623
[TBL] [Abstract][Full Text] [Related]
5. Single-cell RNA sequencing reveals the cellular and molecular heterogeneity of treatment-naïve primary osteosarcoma in dogs.
Ammons DT; Hopkins LS; Cronise KE; Kurihara J; Regan DP; Dow S
Commun Biol; 2024 Apr; 7(1):496. PubMed ID: 38658617
[TBL] [Abstract][Full Text] [Related]
6. Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target.
Gingrich AA; Reiter TE; Judge SJ; York D; Yanagisawa M; Razmara A; Sturgill I; Basmaci UN; Brady RV; Stoffel K; Murphy WJ; Rebhun RB; Brown CT; Canter RJ
Front Immunol; 2021; 12():670309. PubMed ID: 34594320
[TBL] [Abstract][Full Text] [Related]
7. Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.
Dao T; Mun SS; Scott AC; Jarvis CA; Korontsvit T; Yang Z; Liu L; Klatt MG; Guerreiro M; Selvakumar A; Brea EJ; Oh C; Liu C; Scheinberg DA
Oncoimmunology; 2019; 8(7):1570778. PubMed ID: 31143508
[TBL] [Abstract][Full Text] [Related]
8. Role of Periostin Expression in Canine Osteosarcoma Biology and Clinical Outcome.
Alfino LN; Wilczewski-Shirai KC; Cronise KE; Coy J; Glapa K; Ehrhart EJ; Charles JB; Duval DL; Regan DP
Vet Pathol; 2021 Sep; 58(5):981-993. PubMed ID: 33685296
[TBL] [Abstract][Full Text] [Related]
9. Proteomic Analyses Reveal the Role of Alpha-2-Macroglobulin in Canine Osteosarcoma Cell Migration.
Wilk SS; Michalak K; Owczarek EP; Winiarczyk S; Zabielska-Koczywąs KA
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612805
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric analysis of peripheral blood and tumor-infiltrating regulatory T cells in dogs with oral malignant melanoma.
Tominaga M; Horiuchi Y; Ichikawa M; Yamashita M; Okano K; Jikumaru Y; Nariai Y; Kadosawa T
J Vet Diagn Invest; 2010 May; 22(3):438-41. PubMed ID: 20453222
[TBL] [Abstract][Full Text] [Related]
11. Relationship between regulatory and type 1 T cells in dogs with oral malignant melanoma.
Horiuchi Y; Tominaga M; Ichikawa M; Yamashita M; Okano K; Jikumaru Y; Nariai Y; Nakajima Y; Kuwabara M; Yukawa M
Microbiol Immunol; 2010 Mar; 54(3):152-9. PubMed ID: 20236425
[TBL] [Abstract][Full Text] [Related]
12. SAFETY AND TOXICITY OF AN ACCELERATED COARSELY FRACTIONATED RADIATION PROTOCOL FOR TREATMENT OF APPENDICULAR OSTEOSARCOMA IN 14 DOGS: 10 GY × 2 FRACTIONS.
Pagano C; Boudreaux B; Shiomitsu K
Vet Radiol Ultrasound; 2016 Sep; 57(5):551-6. PubMed ID: 27374864
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.
Heaton CM; Fernandes AFA; Jark PC; Pan X
J Vet Intern Med; 2020 Mar; 34(2):873-881. PubMed ID: 31977135
[TBL] [Abstract][Full Text] [Related]
14. A retrospective survey on canine intracranial tumors between 2007 and 2017.
Kishimoto TE; Uchida K; Chambers JK; Kok MK; Son NV; Shiga T; Hirabayashi M; Ushio N; Nakayama H
J Vet Med Sci; 2020 Jan; 82(1):77-83. PubMed ID: 31801930
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Survival and Glycemic Control with Toceranib Phosphate and Prednisone for a Metastatic Canine Insulinoma.
Flesner BK; Fletcher JM; Smithee T; Boudreaux B
J Am Anim Hosp Assoc; 2019; 55(1):e55105. PubMed ID: 30427714
[TBL] [Abstract][Full Text] [Related]
16. Primary appendicular hemangiosarcoma and telangiectatic osteosarcoma in 70 dogs: A Veterinary Society of Surgical Oncology retrospective study.
Giuffrida MA; Kamstock DA; Selmic LE; Pass W; Szivek A; Mison MB; Boston SE; Fox LE; Robat C; Grimes JA; Maritato KC; Bacon NJ
Vet Surg; 2018 Aug; 47(6):774-783. PubMed ID: 30051473
[TBL] [Abstract][Full Text] [Related]
17. Computed tomographic appearance of canine tonsillar neoplasia: 14 cases.
Thierry F; Longo M; Pecceu E; Zani DD; Schwarz T
Vet Radiol Ultrasound; 2018 Jan; 59(1):54-63. PubMed ID: 28929544
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Evaluation of Whole Body Computed Tomography for Tumor Staging in Dogs with Primary Appendicular Osteosarcoma.
Talbott JL; Boston SE; Milner RJ; Lejeune A; Souza CH; Kow K; Bacon NJ; Hernandez JA
Vet Surg; 2017 Jan; 46(1):75-80. PubMed ID: 27906470
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma.
Mason NJ; Gnanandarajah JS; Engiles JB; Gray F; Laughlin D; Gaurnier-Hausser A; Wallecha A; Huebner M; Paterson Y
Clin Cancer Res; 2016 Sep; 22(17):4380-90. PubMed ID: 26994144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
